Core Viewpoint - The announcement from Weisi Medical (688580.SH) reveals that shareholder Nanjing Zhida Venture Capital Center plans to reduce its stake in the company by up to 2,873,137 shares, representing a maximum of 3% of the total share capital, without significantly impacting the company's governance or operational stability [1][2]. Shareholder Reduction Plan - Nanjing Zhida Venture Capital intends to reduce its holdings through two methods: a maximum of 957,712 shares via centralized bidding (1% of total shares) and up to 1,915,425 shares through block trading (2% of total shares), both within three months after 15 trading days from the announcement date [1][2]. - The total cash-out from the planned reduction is approximately ¥180,605,391.82, based on the closing price of ¥62.86 per share on January 16 [2]. Company Background - Weisi Medical was listed on the Shanghai Stock Exchange's Sci-Tech Innovation Board on July 21, 2020, with an initial issuance of 17.0867 million shares at a price of ¥67.58 per share, raising a total of ¥1.155 billion [2]. - The net proceeds from the fundraising amounted to ¥1.063 billion, exceeding the original plan by ¥596 million, which was intended for various projects including R&D and marketing [2]. Shareholder Structure - As of the announcement date, Nanjing Zhida Venture Capital held 6,758,338 shares, accounting for 7.06% of the total share capital, and is in a concerted action relationship with the company's actual controller, Wang Zhiyu [2][4]. - Wang Zhiyu is the executive partner of Nanjing Zhida Venture Capital and holds Canadian permanent residency [4]. Dividend Distribution - The company plans to distribute a cash dividend of ¥1.5032 per share (including tax) and to increase the share capital by 4 shares for every 10 shares held, based on the total share capital after accounting for repurchased shares [4][5]. - The total cash dividend distribution is expected to be approximately ¥102,194,339.48 (including tax), with the adjusted per-share cash dividend amounting to ¥1.5058 [5].

Group 1 - The company approved a share repurchase plan using excess funds, with a total amount between RMB 22.5 million and RMB 45 million, and a maximum repurchase price of RMB 30.00 per share [2][10] - The maximum repurchase price was later adjusted from RMB 30.00 to RMB 53.00 per share [3][11] - Following the implementation of the 2024 annual profit distribution and capital reserve conversion, the maximum repurchase price was further adjusted to RMB 44.02 per share, effective from August 7, 2025 [6][7][11] Group 2 - The company plans to distribute a cash dividend of RMB 2.30 per 10 shares and convert 2 shares for every 10 shares held, with the cash dividend amounting to approximately RMB 33.39 million [4][19] - The total share capital after the conversion will increase to 175,167,650 shares [19][29] - The adjusted maximum repurchase price calculation considers the cash dividend and the change in circulating shares [7][20] Group 3 - As of July 31, 2025, the company had repurchased 588,036 shares, accounting for 0.402% of the total share capital, with a total expenditure of approximately RMB 23.14 million [12] - The highest repurchase price recorded was RMB 49.76 per share, while the lowest was RMB 34.78 per share [12] - The company will continue to comply with relevant regulations during the repurchase period and will disclose progress regularly [8][13]

Group 1 - The company announced a change in registered capital and amendments to its Articles of Association, which were approved during the board meeting on June 13, 2025 [1] - The company plans to distribute a cash dividend of 6.00 RMB per 10 shares and to increase capital by 4.5 shares for every 10 shares held, based on the total share capital of 114,504,414 shares as of May 31, 2025 [1] - The amendments to the Articles of Association will be disclosed on the Shanghai Stock Exchange website and require approval from the shareholders' meeting [1][2] Group 2 - The company will authorize the chairman or designated personnel to handle the necessary registration and filing procedures with the industrial and commercial registration authority [1]